Clinical characteristics and prognostic analysis of SMARCA4 ‐deficient non‐small cell lung cancer
Cancer Medicine · 2023-07 · 12 (13) · 14171-14182
DOI: 10.1002/cam4.6083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.05.2023. Verfasst von Xiyue Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Medical Science and Technique Foundation, National Basic Research Program of China.
Abstract (Originalsprache)
Purpose
To improve the understanding of special types of tumors, we summarized and analyzed the clinicopathological features and prognostic factors of SMARCA4‐deficient non‐small cell lung cancer (SMARCA4‐dNSCLC).
Methods
We selected 105 patients with SMARCA4‐dNSCLC and 221 patients with SMARCA4‐intact non‐small cell lung cancer (SMARCA4‐iNSCLC) by performing immunohistochemical analysis of 1520 NSCLC samples, and we assessed the patients' clinicopathological features and survival state.
Results
(1) SMARCA4‐dNSCLC was significantly associated with older age, male sex, smoking history, larger invasive tumor size, higher tumor proliferation index (Ki‐67), more adrenal metastases, more lymph node metastases, and few EGFR mutations ( p < 0.05). The tumors were mostly negative for thyroid transcription factor‐1 (TTF‐1), CD34, and p40 and positive for cytokeratin 7 (CK7) in immunohistochemistry (IHC). Nineteen SMARCA4‐dNSCLC patients mostly had TP53 , SMARCA4 , and LRP1B mutations, and 48% of them had SMARCA4 frameshift mutations. SMARCA4‐dNSCLC patients have a worse prognosis than SMARCA4‐iNSCLC patients (HR: 0.27; 95% CI: 0.17–0.45). The overall survival (OS) of patients with stage III SMARCA4‐dNSCLC was worse than that of patients with SMARCA4‐iNSCLC, and the OS of stage IV SMARCA4‐dNSCLC patients was also worse than that of SMARCA4‐iNSCLC patients ( p < 0.01). (2) Multivariate regression analysis showed that sex (HR: 4.12; 95% CI: 1.03–16.39) and smoking history (HR: 2.29; 95% CI: 1.04–5.02) had significant effects on the survival time of SMARCA4‐dNSCLC patients. In SMARCA4‐dNSCLC patients without distant metastases (stage I–III), patients with stage N2 or N3 lymph node metastases (HR: 6.35; 95% CI: 1.07–37.47) had a poor prognosis. Among patients with SMARCA4‐dNSCLC who were treated and had distant metastases (stage IV), male patients and patients treated with immunotherapy combined with chemotherapy showed a longer median overall survival (mOS).
Conclusion
SMARCA4‐dNSCLC has unique clinicopathological features and a shorter survival prognosis than SMARCA4‐iNSCLC. The efficacy of immunotherapy combined with chemotherapy needs to be observed for longer periods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Xiyue Liang
Förderung
- Henan Medical Science and Technique Foundation
- National Basic Research Program of China
Zitieren
APA
Liang, X., Gao, X., Wang, F., Li, S., Zhou, Y., Guo, P., Meng, Y., & Lu, T. (2023). Clinical characteristics and prognostic analysis of SMARCA4 ‐deficient non‐small cell lung cancer. Cancer Medicine, 12(13), 14171-14182. https://doi.org/10.1002/cam4.6083
Vancouver
Liang X, Gao X, Wang F, Li S, Zhou Y, Guo P, et al. Clinical characteristics and prognostic analysis of SMARCA4 ‐deficient non‐small cell lung cancer. Cancer Medicine. 2023;12(13):14171-14182. doi:10.1002/cam4.6083
BibTeX
@article{Liang2023,
author = {Liang, Xiyue and Gao, Xianzheng and Wang, Feng and Li, Shenglei and Zhou, Yashu and Guo, Peng and Meng, Yuanyuan and Lu, Taiying},
title = {Clinical characteristics and prognostic analysis of SMARCA4 ‐deficient non‐small cell lung cancer},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {13},
pages = {14171--14182},
doi = {10.1002/cam4.6083}
}
EUVIMED